Literature DB >> 8435997

The safety and efficacy issues of progestin-only oral contraceptives--an epidemiologic perspective.

I Chi1.   

Abstract

Progestogen-only oral contraceptives (POCs) are generally considered a good contraceptive choice for brestfeeding women and for women who want to use an oral form of contraception, but are not suited for, or cannot tolerate the side effects of, estrogen-containing preparations. However, a number of POCs' safety, efficacy and other related issues remain to be addressed. This paper reviews recent literature and evaluates these issues from an epidemiologic perspective. The small number of users imposes severe limitations in designing epidemiologic studies to address POCs' long-term safety issues, but available information suggests POCs are at least as safe as, if not safer than, COCs. Compared to COCs, POCs are more likely to cause menstrual disturbances which, in turn, could affect their acceptability and lead to poor compliance and hence higher pregnancy rates. POCs' efficacy has been estimated to be between 1.4 and 4.3 pregnancies per 100 woman-years of use. Lower pregnancy rates approaching those of COCs have been reported in centers with good counseling. POCs' benefits outweigh their risks. However, more studies are needed to further address POCs' safety and efficacy issues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435997     DOI: 10.1016/0010-7824(93)90105-g

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  2 in total

Review 1.  Managing women with gestational diabetes mellitus in the postnatal period.

Authors:  Catherine Kim
Journal:  Diabetes Obes Metab       Date:  2009-09-25       Impact factor: 6.577

2.  The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception.

Authors:  Jessica Atrio; Alice Stek; Hita Vora; Lorraine Sanchez-Keeland; Ferdous Zannat; Melissa Natavio
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-10-06       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.